CRMD CorMedix Inc.

CIK 0001410098 50 ready 8-Ks latest June 8, 2026, 8:45 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 7, 2026, 4:18 PM ET

Top materiality 0.95

Event mix earnings ×18 · other_material ×10 · regulatory ×8

Sentiment 25 pos · 4 neg · 21 neu

Latest earnings ▲ beat 2025-FY

Executive change recent →

Recent 8-K filings for CRMD

Highest-materiality recent filing

CorMedix announces FDA approval of DefenCath to reduce catheter-related bloodstream infections in hemodialysis patients

November 16, 2023, 6:59 PM ET regulatory materiality 0.95 positive item 8.01 item 9.01

DefenCath (taurolidine and heparin) is the first FDA-approved antimicrobial catheter lock solution for adult hemodialysis patients.
Phase 3 LOCK-IT-100 trial showed a statistically significant 71% reduction in risk of CRBSIs (Hazard Ratio 0.29).

Read filing →

June 8, 2026, 8:45 AM ET litigation materiality 0.75 positive item 7.01 item 9.01

Federal Circuit upholds CorMedix's MINOCIN patents; Nexus generic barred from market

Federal Circuit affirmed district court: Nexus generic minocycline infringes two CorMedix patents, invalidity rejected.
May 14, 2026, 7:34 AM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

CorMedix Q1 net revenue $127.4M, net income $38.6M; raises FY guidance

Q1 net revenue $127.4M, net income $38.6M, adjusted EBITDA $70.0M; EPS $0.48 basic/$0.43 diluted.
April 27, 2026, 7:59 PM ET other material materiality 0.90 positive item 7.01 item 9.01

CorMedix reports positive Phase III ReSPECT results for REZZAYO in fungal prophylaxis

Primary endpoint met: fungal-free survival at Day 90 was 60.7% for rezafungin vs 59.0% for standard regimen.
March 6, 2026, 6:59 PM ET other material materiality 0.70 neutral item 7.01 item 9.01

CorMedix reaffirms FY2027 DefenCath guidance $100M-$140M; FY2026 revenue guidance $300M-$320M

Reaffirms FY2027 DefenCath sales $100M-$140M, correcting inadvertent $100M-$125M range from March 5 earnings call.
March 5, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

CorMedix Q4 rev $128.6M; FY2025 net income $163M; reiterates 2026 guidance

Q4 net revenue $128.6M ($91.2M DefenCath, $37.4M Melinta); net income $14.0M vs $13.5M YoY.
January 8, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 5.02 item 8.01 item 9.01

CorMedix preliminary Q4 revenue ~$127M, FY2025 pro forma ~$400M; CEO becomes Chairman, new CCO appointed

Q4 2025 unaudited net revenue ~$127M; FY2025 pro forma net rev. ~$400M (incl. Melinta).
November 12, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

CorMedix reports Q3 net income of $108.6M, raises FY 2025 pro forma revenue guidance to $390-410M

Net revenue of $104.3M (pro forma $130.8M) driven by DefenCath sales of $88.8M; diluted EPS $1.26.
October 20, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CorMedix Q3 prelim rev >$100M, raises FY25 pro forma guidance to at least $375M

Q3 2025 preliminary net revenue >$100M; DefenCath revenue >$85M; pro forma net revenue >$125M.
September 30, 2025, 7:59 PM ET M&A materiality 0.60 neutral item 9.01

CorMedix files Melinta acquisition financials; Melinta 2024 revenue $120M, net loss $4.7M

Melinta 2024 total revenue $119.97M (product $106.3M) vs $105.6M in 2023; net loss narrowed to $4.7M from $36.0M.
September 2, 2025, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01 ◈ M&A Transactions

CorMedix completes $300M acquisition of Melinta; raises FY2025 revenue guidance

Acquisition closed Aug 29, 2025; $260M cash + $40M equity upfront, plus up to $25M in milestone payments.
August 12, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 3.02 item 9.01

CorMedix closes $150M convertible note offering due 2030 at 4.00% interest

Issued $150M aggregate principal of 4.00% Convertible Senior Notes due 2030 in a private placement.
August 7, 2025, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 2.02 item 3.02 item 7.01 item 8.01 item 9.01

CorMedix to acquire Melinta for $300M; Q2 revenue $39.7M, net income $19.8M

Enters agreement to acquire Melinta for $260M cash + $40M stock, plus contingent milestone payments up to $25M and tiered royalties on REZZAYO and MINOCIN.
June 30, 2025, 7:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

CorMedix closes $85M public offering of common stock, net proceeds $82.2M

Closed public offering of 6,604,507 shares at gross proceeds ~$85M.
June 23, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

CorMedix raises Q2 net sales guidance to $35-40M; LDO customer implements DefenCath with 50%+ more patients

LDO customer commenced ordering DefenCath; implementation targets at least 50% more patients than previously communicated.
May 6, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

CorMedix Q1 2025 net revenue $39.1M, net income $20.6M vs loss; raises H1 guidance to high-end

Q1 net revenue $39.1M; net income $20.6M ($0.32 EPS) vs net loss of $14.5M ($0.25 loss) in Q1 2024.
April 8, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

CorMedix Q1 prelim revenue $39.0M, raises H1 2025 net sales guidance to $62-$70M

Preliminary unaudited Q1 2025 net revenue of $39.0M; expects adjusted EBITDA above $22.5M.
March 25, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

CorMedix Q4 2024 net revenue $31.2M, first profitable quarter; H1 2025 guidance $50-60M

Q4 2024 net revenue $31.2M; net income $13.5M ($0.22/diluted share); adjusted EBITDA $15.3M.
January 7, 2025, 6:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01

CorMedix reports preliminary Q4 2024 net revenue ~$31M, FY ~$43M; Q4 Adj EBITDA >$12M

Q4 2024 prelim unaudited net revenue ~$31M; FY 2024 ~$43M; Q4 Adj EBITDA >$12M.
October 30, 2024, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

CorMedix Q3 net revenue $11.5M; net loss narrows to $2.8M; DefenCath access at 60% of US clinics

Q3 2024 net revenue of $11.5M from DefenCath first full quarter; net loss $2.8M ($0.05/sh) vs $9.7M loss ($0.17/sh) in Q3 2023.
August 14, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

CorMedix Q2 net loss $14.2M; DefenCath sales $0.8M initial, outpatient QTD $5.2M

Q2 net loss $14.2M ($0.25/share) vs $11.3M loss ($0.25/share) a year ago, driven by higher operating expenses.
May 9, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

CorMedix Q1 net loss $14.5M; launches DefenCath; CMS TDAPA effective July 2024

Net loss of $14.5M ($0.25/sh) vs $10.6M loss ($0.24/sh) in Q1 2023; operating expenses up 44% to $15.9M.
March 12, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

CorMedix reports Q4 2023 net loss $14.8M; FDA approved DefenCath; launch April 2024

Net loss Q4 2023 $14.8M ($0.26/sh) vs $8.2M ($0.20/sh) Q4 2022; operating expenses $15.7M.
January 30, 2024, 6:59 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

CorMedix receives CMS reimbursement determination for DefenCath; sets WAC price at $249.99 per vial

CMS determined DefenCath eligible for ESRD PPS reimbursement; CorMedix submitted TDAPA application for 5-year add-on payment.
November 16, 2023, 6:59 PM ET regulatory materiality 0.95 positive item 8.01 item 9.01

CorMedix announces FDA approval of DefenCath to reduce catheter-related bloodstream infections in hemodialysis patients

DefenCath (taurolidine and heparin) is the first FDA-approved antimicrobial catheter lock solution for adult hemodialysis patients.
August 8, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

CorMedix Q2 net loss widens to $11.3M; DefenCath NDA PDUFA date Nov 15, 2023

Net loss of $11.3M ($0.25 per share) vs $7.6M loss in Q2 2022, driven by increased R&D and SG&A.
June 30, 2023, 7:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

CorMedix prices $40M public offering of 7.5M shares at $4.00/sh and pre-funded warrants

Gross proceeds ~$40M from 7.5M shares at $4.00/sh and 2.5M pre-funded warrants at $3.999.
June 21, 2023, 7:59 PM ET regulatory materiality 0.60 positive item 8.01 item 9.01

CorMedix announces FDA acceptance of DefenCath NDA resubmission; PDUFA date Nov 15, 2023

FDA accepted DefenCath NDA resubmission as a complete Class 2 response with six-month review.
May 16, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

CorMedix resubmits DefenCath NDA to FDA for hemodialysis catheter infection prevention

NDA for DefenCath resubmitted to FDA as of May 15, 2023; agency acknowledged receipt for processing.
May 15, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

CorMedix Q1 net loss $10.6M; DefenCath NDA resubmitted to FDA for 6-month review

Q1 net loss $10.6M ($0.24/share) vs $7.0M loss in Q1 2022; operating expenses $11.0M, up 57% YoY due to pre-launch activities.
April 26, 2023, 7:59 PM ET regulatory materiality 0.65 positive item 8.01 item 9.01

CorMedix to resubmit DefenCath NDA by mid-May; CMS proposes NTAP up to $17,111

Company will resubmit NDA for DefenCath to FDA by mid-May 2023 following Type A meeting.
March 30, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

CorMedix reports Q4 2022 net loss $8.2M; FDA grants Type A meeting for DefenCath resubmission

Q4 2022 net loss $8.2M ($0.20/shr) vs $7.8M loss in Q4 2021; full-year net loss $29.7M ($0.74/shr).
March 3, 2023, 6:59 PM ET regulatory materiality 0.85 neutral item 8.01 item 9.01

CorMedix updates DefenCath NDA resubmission pathways; CMO 1 completes corrective actions

CMO 1 completed all corrective actions from FDA's June 2022 inspection; awaits FDA feedback on compliance status.
November 10, 2022, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

CorMedix reports Q3 net loss of $6.9M; provides DefenCath regulatory and NTAP updates

Net loss of $6.9M ($0.17 per share) improved from $8.6M loss ($0.22) in Q3 2021.
August 11, 2022, 7:59 PM ET regulatory materiality 0.85 negative item 2.02 item 9.01

CorMedix receives second FDA CRL for DefenCath; Q2 net loss $7.6M

Second CRL from FDA for DefenCath NDA due to unresolved deficiencies at CMO and heparin supplier.
August 9, 2022, 7:59 PM ET regulatory materiality 0.85 negative item 8.01 item 9.01

CorMedix receives second Complete Response Letter from FDA for DefenCath NDA due to manufacturing deficiencies

FDA issued second CRL stating DefenCath NDA cannot be approved until deficiencies at CMO and heparin supplier are resolved.
May 12, 2022, 7:59 PM ET other material materiality 0.85 positive item 2.02 item 8.01 item 9.01

CorMedix: Q1 net loss $7.0M; FDA accepts DefenCath NDA resubmission with 6-mo review

Net loss $7.0M ($0.18/shr) vs $7.2M ($0.20/shr) in Q1 2021; operating expenses down 3%.

Executive changes

Departed

Phoebe Mounts

Executive Vice President, General Counsel and Corporate Secretary

CRMD · CorMedix Inc.

Effective: 2023-12-31
Filed: December 15, 2023, 6:59 PM ET

On December 12, 2023, upon mutual agreement between CorMedix Inc. (the “Company”) and Phoebe Mounts, Ph.D., Esq., the Company’s Executive Vice President, General Counsel and Corporate Secretary, the Board of Directors of the Company (the “Board”) approved the separation of employment of Dr. Mounts, effective December 31, 2023

Departed

Paulo F. Costa

Member of the Board of Directors

CRMD · CorMedix Inc.

Effective: 2023-10-15
Filed: August 17, 2023, 7:59 PM ET

On August 14, 2023, Paulo F. Costa, a member of the Board of Directors (the “Board”) of CorMedix Inc. (the “Company”), notified the Board that he will be retiring from the Board, effective as of October 15, 2023.

Appointed

Robert Stewart

Director

CRMD · CorMedix Inc.

Effective: 2023-04-13
Filed: April 17, 2023, 7:59 PM ET

On April 13, 2023, the Board of Directors (the “Board”) of CorMedix Inc. (the “Company”) appointed Robert Stewart as a director, effective immediately

Appointed

Joseph Todisco

Chief Executive Officer

CRMD · CorMedix Inc.

Filed: March 21, 2022, 7:59 PM ET

appointed Joseph Todisco as the Chief Executive Officer, commencing on such date as mutually agreed by Mr. Todisco and the Board, but in no event later than May 16, 2022.

Appointed

Joseph Todisco

Director

CRMD · CorMedix Inc.

Effective: 2022-03-18
Filed: March 21, 2022, 7:59 PM ET

Mr. Todisco was appointed to serve as a member of the Board on March 18, 2022.

Role change

Matthew T. David

Chief Financial Officer

CRMD · CorMedix Inc.

Successor: Joseph Todisco
Filed: March 21, 2022, 7:59 PM ET

Dr. Matthew T. David will continue to serve as Interim Chief Executive Officer and Chief Financial Officer until Mr. Todisco commences employment, after which Dr. David will continue to serve as our Chief Financial Officer.

Role change (interim)

Matt David

interim Chief Executive Officer

CRMD · CorMedix Inc.

Effective: 2021-10-26
Filed: October 29, 2021, 7:59 PM ET

On October 26, 2021, CorMedix Inc. (“Company”) and Matt David, M.D., the Company’s current Chief Financial Officer, entered into a letter agreement (the “Letter Agreement”) modifying certain terms of his employment agreement with the Company, dated May 11, 2020 (“Employment Agreement”), and providing other compensation, as a result of Dr. David serving as interim Chief Executive Officer of the Company.

Appointed (interim)

Matthew David

Interim Chief Executive Officer

CRMD · CorMedix Inc.

Effective: 2021-10-04
Filed: October 5, 2021, 7:59 PM ET

Matthew David, M.D., the Company’s current Chief Financial Officer, will serve as interim Chief Executive Officer, effective immediately, until a new Chief Executive Officer is appointed.

Departed

John L. Armstrong, Jr.

Executive Vice President, Technical Operations

CRMD · CorMedix Inc.

Effective: 2021-10-04
Filed: October 5, 2021, 7:59 PM ET

On October 4, 2021, the Company and John L. Armstrong, Jr. came to a mutual agreement pursuant to which Mr. Armstrong will retire from his position as the Company’s Executive Vice President, Technical Operations, effective October 4, 2021.

Departed (interim)

Khoso Baluch

Chief Executive Officer

CRMD · CorMedix Inc.

Effective: 2021-10-04
Successor: Matthew David
Filed: October 5, 2021, 7:59 PM ET

On October 1, 2021, the Company and Khoso Baluch came to a mutual agreement pursuant to which Mr. Baluch will retire from his position as the Company’s Chief Executive Officer, effective October 4, 2021.

Earnings & guidance

2025-FY EPS reported $2.04 vs consensus $0.83 ▲ beat (+145.0%) filing →

Materiality & sentiment trend

Max materiality 0.95 · Median 0.70 · Most common event earnings

25 positive 4 negative 21 neutral

source · CRMD on sec.gov